Virtual Event | Latest Data in Breast Cancer Response
Monitoring and Relapse Prediction
Following SABCS, learn about the latest advances and clinical data in monitoring response to treatment and identifying patients at high risk of relapse in breast cancer.
Join us for a discussion of data showcasing the validity and utility of using circulating tumor DNA (ctDNA) across neoadjuvant, post-surgical / adjuvant, and metastatic settings, including:
We will cover the latest clinical data from 2021 and 2020 publications and presentations (including SABCS and Nature), prospective studies leveraging ctDNA to enroll breast cancer patients, as well as discuss future implications for clinical trials and clinical practice
Angel Rodriguez, MD
Medical Director, Oncology
Dr. Angel Augusto Rodriguez is a board certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.
John Simmons, PhD
Global Vice President, Biopharma Business Development
John Simmons leads oncology biopharma partnerships at Natera. He received his Bachelor of Science degree in Biology at American University, graduating with Honors. John earned his PhD in Tumor Biology from Georgetown University. Before joining Natera, he completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx).
Date: Tuesday, December 14, 2021
Time: 1pm ET / 10am PT
Duration: 1 Hour
Register now for this webinar